ALX Oncology

ALX Oncology

Contracts Attorney

South San Francisco, CA | $260K - $320K

Apply for job

Company information

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology’s lead product candidate, evorpacept (also known as ALX148), is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.

Linkedin Icon
11-50 employees
Biotechnology, Pharmaceuticals, Healthcare, Oncology, Immuno-oncology
Public Company
Last round: Nov 5, 2023
Last round: US$ 63.2M
South San Francisco, California
Company Specialties:
Immuno-Oncology, Novel Biologics, Research and Development, Innovation, and CD47